Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TET Regimen for Hormone-Refractory Prostate Cancer
NCT00046826Phase 2Completed
- Sponsor
- Nuvance Health
- Start
- Sep 2001
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of thalidomide in prostate cancer (PCa), sponsored by Nuvance Health. Primary endpoint: Objective Response Rate at 1 year. Started Sep 2001; status: completed.
02
Drugs
thalidomide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00046826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00046826.